Drug intelligence / Profile preview

rocuronium + remifentanil

Development stage
Unknown
Lead developer
Merck
Modality
Small Molecules
Administration
Intravenous
01

Overview

Rocuronium + remifentanil is a combination of two intravenous drugs commonly used in anesthesia. Rocuronium is a non-depolarizing neuromuscular blocking agent (muscle relaxant) that acts as a competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, leading to skeletal muscle relaxation and facilitating tracheal intubation or surgery. Remifentanil is an ultra-short-acting synthetic opioid analgesic that acts as an agonist at µ-opioid receptors, providing potent pain relief and blunting hemodynamic responses during surgical procedures. Remifentanil has rapid onset and offset due to its unique metabolism by nonspecific esterases in blood and tissues, independent of liver function[1][3][4][6]. The combination is used for induction and maintenance of general anesthesia, with remifentanil often administered before rocuronium to reduce withdrawal movements caused by rocuronium injection[2].

Other names
rocuronium bromideremifentanil hydrochloride
02

Targets

KOR (Kappa opioid receptor)MOR (Mu opioid receptor)Nicotinic Acetylcholine ReceptorDOR (Opioid Receptor Delta 1)

Beyond the preview

Go deeper on rocuronium + remifentanil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on rocuronium + remifentanil.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call